| Breast tumor kinase (protein tyrosine kinase 6) regulates heregulin-induced activation of ERK5 and p38 MAP kinases in breast cancer cells JH Ostrander, AR Daniel, K Lofgren, CG Kleer, CA Lange Cancer research 67 (9), 4199-4209, 2007 | 169 | 2007 |
| Control of lung vascular permeability and endotoxin-induced pulmonary oedema by changes in extracellular matrix mechanics A Mammoto, T Mammoto, M Kanapathipillai, C Wing Yung, E Jiang, ... Nature communications 4 (1), 1759, 2013 | 153 | 2013 |
| Mechanisms of HGF/Met signaling to Brk and Sam68 in breast cancer progression A Locatelli, KA Lofgren, AR Daniel, NE Castro, CA Lange Hormones and Cancer 3, 14-25, 2012 | 66 | 2012 |
| Breast tumor kinase (Brk/PTK6) is a mediator of hypoxia-associated breast cancer progression TM Regan Anderson, DL Peacock, AR Daniel, GK Hubbard, KA Lofgren, ... Cancer research 73 (18), 5810-5820, 2013 | 61 | 2013 |
| Amphiregulin is a critical downstream effector of estrogen signaling in ERα-positive breast cancer EA Peterson, EC Jenkins, KA Lofgren, N Chandiramani, H Liu, E Aranda, ... Cancer research 75 (22), 4830-4838, 2015 | 57 | 2015 |
| Mammary gland specific expression of Brk/PTK6 promotes delayed involution and tumor formation associated with activation of p38 MAPK KA Lofgren, JH Ostrander, D Housa, GK Hubbard, A Locatelli, RL Bliss, ... Breast Cancer Research 13, 1-17, 2011 | 44 | 2011 |
| Mutant GATA3 actively promotes the growth of normal and malignant mammary cells N Emmanuel, KA Lofgren, EA Peterson, DR Meier, EH Jung, PA Kenny Anticancer research 38 (8), 4435-4441, 2018 | 34 | 2018 |
| Anti-tumor efficacy of an MMAE-conjugated antibody targeting cell surface TACE/ADAM17-cleaved Amphiregulin in breast cancer KA Lofgren, S Sreekumar, EC Jenkins Jr, KJ Ernzen, PA Kenny Antibody Therapeutics 4 (4), 252-261, 2021 | 11 | 2021 |
| Acquisition of cabozantinib-sensitive MET D1228N mutation during progression on crizotinib in MET-amplified triple-negative breast cancer BM Parsons, DR Meier, CS Richmond, GT Gurda, KA Lofgren, ... Clinical Breast Cancer 20 (4), e433-e438, 2020 | 9 | 2020 |
| Amphiregulin deletion strongly attenuates the development of estrogen receptor-positive tumors in p53 mutant mice DR Meier, MA Girtman, KA Lofgren, PA Kenny Breast Cancer Research and Treatment 179, 653-660, 2020 | 8 | 2020 |
| Exceptional response to crizotinib in an MET-amplified triple-negative breast tumor BM Parsons, DR Meier, GT Gurda, KA Lofgren, PA Kenny JCO precision oncology 1, 1-6, 2017 | 8 | 2017 |
| Genomic analysis of melanoma evolution following a 30‐year disease‐free interval JJ Miller, KA Lofgren, SR Hughes, SE Cash, PA Kenny Journal of Cutaneous Pathology 44 (9), 805-808, 2017 | 7 | 2017 |
| Pan-cancer distribution of cleaved cell-surface amphiregulin, the target of the GMF-1A3 antibody drug conjugate KA Lofgren, NC Reker, S Sreekumar, PA Kenny Antibody Therapeutics 5 (3), 226-231, 2022 | 2 | 2022 |
| Exceptional responses to crizotinib in breast cancer patients with somatic MET and ROS1 alterations BM Parsons, DR Meier, S Sreekumar, CS Richmond, KJ Ernzen, ... Cancer Research 79 (13_Supplement), 1317-1317, 2019 | 2 | 2019 |
| Grb7 knockout mice develop normally but litters born to knockout females fail to thrive KA Lofgren, PA Kenny Developmental Dynamics, 2023 | 1 | 2023 |
| Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient BM Parsons, DR Meier, GT Gurda, KA Lofgren, PA Kenny Cancer Research 78 (13_Supplement), 1822-1822, 2018 | 1 | 2018 |
| An instructive ductal microenvironment is key for efficient in vivo modeling of estrogen receptor positive breast cancer KA Lofgren, PA Kenny Translational Cancer Research 5 (2), S360-S362, 2016 | 1 | 2016 |
| Correction: Breast Tumor Kinase (Brk/PTK6) Is a Mediator of Hypoxia-Associated Breast Cancer Progression A Regan, DL PEACOCK, AR DANIEL, GK HUBBARD, KA LOFGREN, ... Cancer research 73 (21), 2013 | 1* | 2013 |
| Antibodies targeting an amphiregulin-derived cell surface neo-epitope PA Kenny, KA Lofgren, S Sreekumar US Patent 12,043,671, 2024 | | 2024 |
| Gemcitabine combination therapies induce apoptosis in uterine carcinosarcoma patient-derived organoids MJ Dahl, KA Lofgren, C Haugen, GE Harmon, SP Hughes, ... Frontiers in Oncology 14, 1368592, 2024 | | 2024 |
